---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-023798"
form_type: "8-K"
ticker: "LIXT"
cik: "0001335105"
company_name: "LIXTE BIOTECHNOLOGY HOLDINGS, INC."
filed_at: "2024-06-14T23:59:59+00:00"
generated_at: "2026-06-01T04:16:08.393758+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lixte enters Phase 1b/2 trial of LB-100 + atezolizumab for metastatic colorectal cancer with NKI

## Summary
- Trial combines Lixte's PP2A inhibitor LB-100 with Roche's atezolizumab; company provides LB-100 only.
- Roche provides atezolizumab and financial support; Lixte has no obligation to reimburse trial costs.
- Phase 1b/2 study led by Dr. Neeltje Steeghs at NKI in Amsterdam; opens by June 30, 2024.
- Patient accrual up to 24 months; maximum 37 metastatic microsatellite stable colorectal cancer patients.
- Dose escalation to determine RP2D; expansion phase evaluates safety, tolerability, and pharmacokinetics.

## SEC filing metadata
- accession: 0001493152-24-023798
- form_type: 8-K
- ticker: LIXT
- cik: 0001335105
- company_name: LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- filed_at: 2024-06-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1335105/000149315224023798/0001493152-24-023798-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1335105/000149315224023798/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-023798
- JSON: https://secwatch.observer/filing/0001493152-24-023798.json
- Plain text: https://secwatch.observer/filing/0001493152-24-023798.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.